| 25.66 -0.04 (-0.16%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 30.06 | 1-year : | 35.11 |
| Resists | First : | 25.73 | Second : | 30.06 |
| Pivot price | 24.58  |
|||
| Supports | First : | 23.65 | Second : | 22.36 |
| MAs | MA(5) : | 25.16 |
MA(20) : | 24.42 |
| MA(100) : | 22.4 |
MA(250) : | 23.03 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 93.3 |
D(3) : | 89.2 |
| RSI | RSI(14): 71.9  |
|||
| 52-week | High : | 26.56 | Low : | 19.24 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FMS ] has closed above the upper band by 2.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 0% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.75 - 25.88 | 25.88 - 26 |
| Low: | 25.01 - 25.16 | 25.16 - 25.29 |
| Close: | 25.4 - 25.67 | 25.67 - 25.89 |
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Fri, 31 Jul 2026
Fresenius Medical Care AG expected to post earnings of 44 cents a share - Earnings Preview - TradingView
Thu, 30 Jul 2026
Fresenius Medical Care AG (FMS) Shares Surge 3.4% -- What GF Sco - GuruFocus
Thu, 30 Jul 2026
BNP Paribas Exane Upgrades Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) to "Strong Sell" - MarketBeat
Wed, 29 Jul 2026
Fresenius Medical Care Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Wed, 29 Jul 2026
Fresenius Medical Care (NYSE: FMS) details BEACON-US real-world study on high-volume hemodiafiltration - Stock Titan
Mon, 27 Jul 2026
Fresenius Medical Care AG : Release of a capital market information - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 537 (M) |
| Shares Float | 368 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.6 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 2,840 (K) |
| EPS | 1.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 27.97 |
| Profit Margin | 4.8 % |
| Operating Margin | 8.1 % |
| Return on Assets (ttm) | 3.6 % |
| Return on Equity (ttm) | 7.8 % |
| Qtrly Rev. Growth | -5.5 % |
| Gross Profit (p.s.) | 9.34 |
| Sales Per Share | 36.04 |
| EBITDA (p.s.) | 4.82 |
| Qtrly Earnings Growth | -17.2 % |
| Operating Cash Flow | 2,750 (M) |
| Levered Free Cash Flow | 1,670 (M) |
| PE Ratio | 13.72 |
| PEG Ratio | 0.8 |
| Price to Book value | 0.91 |
| Price to Sales | 0.71 |
| Price to Cash Flow | 5.01 |
| Dividend | 0.87 |
| Forward Dividend | 0 |
| Dividend Yield | 3.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|